Table 4.
Model Parameter | AS Base Case | Threshold Value at Which AS QALE is Equal to or BETTER Than WW QALE |
---|---|---|
Men aged 65 y | ||
HR for prostate cancer-specific death for treatment vs. AS | 1.85 | ≥7.71 |
Lifetime probability of being treated on AS, % | 78 | ≤63 |
Utility of AS at which AS if favored over WW | 0.83 | ≥0.87 |
Men aged 75 y | ||
HR for prostate cancer-specific death for treatment vs. AS | 1.85 | ≥4.30 |
Lifetime probability of being treated on AS, % | 61 | ≤42 |
Utility of AS at which AS if favored over WW | 0.83 | ≥0.84 |
AS = active surveillance; HR = hazard ratio; QALE = quality-adjusted life expectancy; WW = watchful waiting.
WW remains less expensive than AS under every reasonable scenario modeled.